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PMyocardial Scar Visualized by Cardiovascular
Magnetic Resonance Imaging Predicts Major Adverse
Events in Patients With Hypertrophic Cardiomyopathy
Oliver Bruder, MD,* Anja Wagner, MD,† Christoph J. Jensen, MD,* Steffen Schneider, PHD,‡
Peter Ong, MD,§ Eva-Maria Kispert, RN,§ Kai Nassenstein, MD, Thomas Schlosser, MD,
Georg V. Sabin, MD,* Udo Sechtem, MD,§ Heiko Mahrholdt, MD§
Essen, Ludwigshafen, and Stuttgart, Germany; and Philadelphia, Pennsylvania
Objectives We sought to establish the prognostic value of a comprehensive cardiovascular magnetic resonance (CMR) ex-
amination in risk stratification of hypertrophic cardiomyopathy (HCM) patients.
Background With annual mortality rates ranging between 1% and 5%, depending on patient selection, a small but significant
number of HCM patients are at risk for an adverse event. Therefore, the identification of and prophylactic ther-
apy (i.e., defibrillator placement) in patients with HCM who are at risk of dying are imperative.
Methods Two-hundred forty-three consecutive patients with HCM were prospectively enrolled. All patients underwent initial
CMR, and 220 were available for clinical follow-up. The mean follow-up time was 1,090 days after CMR. End
points were all-cause and cardiac mortality.
Results During follow-up 20 of the 220 patients died, and 2 patients survived sudden cardiac death due to adequate
implantable cardioverter-defibrillator discharge. Most events (n  16) occurred for cardiac reasons; the remain-
ing 6 events were related to cancer and accidents. Our data indicate that the presence of scar visualized by CMR
yields an odds ratio of 5.47 for all-cause mortality and of 8.01 for cardiac mortality. This might be superior to
classic clinical risk factors, because in our dataset the presence of 2 risk factors yields an odds ratio of 3.86 for
all-cause and of 2.20 for cardiac mortality, respectively. Multivariable analysis also revealed the presence of late
gadolinium enhancement as a good independent predictor of death in HCM patients.
Conclusions Among our population of largely low or asymptomatic HCM patients, the presence of scar indicated by CMR is a
good independent predictor of all-cause and cardiac mortality. (J Am Coll Cardiol 2010;56:875–87) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.007s
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cypertrophic cardiomyopathy (HCM) is the most common
enetic cardiovascular disorder (1). With annual mortality
ates ranging between 1% and 5% depending on patient
election, a small but significant number of patients are at
isk for an adverse event (2). Therefore, the identification
nd prophylactic therapy (i.e., defibrillator placement) in
atients with HCM who are at risk of dying are imperative.
his is underscored by the fact that HCM has a high
rom the *Department of Cardiology and Angiology, Elisabeth Hospital, Essen,
ermany; †Department of Cardiology, Hahnemann University Hospital, Drexel
ollege of Medicine, Philadelphia, Pennsylvania; ‡Institut für Herzinfarktforschung,
udwigshafen, Germany; §Department of Cardiology, Robert Bosch Medical Cen-
er, Stuttgart, Germany; and the Department of Diagnostic and Interventional
adiology, University Hospital, Essen, Germany. All authors have reported that they
ave no relationships to disclose.o
Manuscript received March 30, 2010; revised manuscript received May 13, 2010,
ccepted May 17, 2010.ocioeconomic impact, because it is the most common cause
or sudden cardiac death (SCD) in young people (3).
Currently, several clinical markers are accepted for risk
tratification in patients with HCM, including an adverse
amily history, prior cardiac arrest, spontaneous ventricular
achycardias or syncope, left ventricular (LV) wall thickness,
nd ventricular outflow tract obstruction. However, risk
tratification in HCM is still limited by low positive
redictive values of the clinical markers described in the
receding text (4,5).
See page 888
Recently, it has been described that myocardial scarring
etected by late gadolinium enhancement (LGE) cardiovas-
ular magnetic resonance (CMR) is related to long-term
linical outcome and thus might be a much better predictor
f lethal adverse events (Fig. 1) than established clinical
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Cardiovascular Magnetic Resonance Risk Stratification in HCM September 7, 2010:875–87markers (6). Consequently, the
primary objective of this study
was to establish the prognostic
value of a comprehensive CMR
examination in risk stratification
of patients with hypertrophic
cardiomyopathy. Specifically, we
sought to demonstrate that the
presence of scar visualized by
CMR predicts future cardiac
death. In addition, we aimed to
compare the incremental value of
different CMR parameters in
predicting adverse events with
that of the established clinical
markers.
Methods
Patient population. Two-hundred
forty-three consecutive patients
presenting at our institutions in
Essen and Stuttgart for work-up
f known or suspected HCM were prospectively enrolled
etween January 2003 and April 2008. All patients gave
nformed consent to the protocol, which was approved by
Abbreviations
and Acronyms
CCS  Canadian
Cardiovascular Society
angina score
CMR  cardiovascular
magnetic resonance
EF  ejection fraction
HCM  hypertrophic
cardiomyopathy
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LGE  late gadolinium
enhancement
LV  left ventricle/
ventricular
LVOT  left ventricular
outflow tract
SCD  sudden cardiac
death
Figure 1 CMR Images of a 48-Year-Old White Man With 3 Reco
Case #107. Cine images in the top and middle rows reveal normal left ventric
ize extensive scarring as indicated by late gadolinium enhancement (LGE) (whi
implantable cardioverter-defibrillator (ICD) placement shortly after cardiovascula
cardiac death (SCD), due to 2 adequate ICD discharges in the setting of ventrihe local institutional review boards, and underwent CMR
s well as centralized clinical follow-up. The HCM was
iagnosed (or confirmed) by the presence of a nondilated
nd hypertrophied LV on 2-dimensional echocardiography
r CMR (maximal wall thickness 15 mm in adult index
atients or 13 mm in adult relatives of HCM patients) in
he absence of another disease that could account for the
ypertrophy (7). Patients who were known to have coronary
rtery disease, aortic stenosis, amyloidosis, systemic hyper-
ension, or contraindications to CMR imaging were not
ncluded. We also did not include patients with previous
eptal ablation or myectomy.
MR protocol. All images were acquired on a 1.5-T
canner (Siemens Sonata or Siemens Avanto, Siemens
ealthcare, Erlangen, Germany) with a phased array re-
eiver coil during breath-holds (approximately 8 s) gated to
he electrocardiogram. Cine images were acquired in mul-
iple short-axis and 2 to 3 long-axis views with a steady state
ree precession technique (8). Short-axis views were pre-
cribed every 10 mm (slice thickness 6 mm) from base to
pex (6 to 8 cine slices/heart) (9). A gadolinium-based
ontrast agent (gadolinium diethylenetriamine penta-acetic
cid or gadoteridol, 0.15 mmol/kg) was then administered
ntravenously, and contrast-enhanced images were acquired
n the same views used for cine imaging on average 10 min
d Clinical Risk Factors for SCD
nction but massive septal hypertrophy. Contrast images (bottom row) visual-
ws). With regard to 3 clinical risk factors (Table 3), this patient underwent
netic resonance (CMR). During follow-up this individual survived sudden
brillation.gnize
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September 7, 2010:875–87 Cardiovascular Magnetic Resonance Risk Stratification in HCMfter contrast administration with a segmented inversion-
ecovery sequence constantly adjusting the inversion time as
escribed previously (10). In-plane image resolution for cine
nd contrast was typically 1.2  1.6 mm.
MR analysis. For all patients, the CMR scans were
laced in random order after the identity markers were
emoved. Two blinded observers evaluated the cine and
ontrast-enhanced images separately.
The endocardial and epicardial borders of the myocar-
ium were planimetered on the short-axis cine images (11).
aximum wall thickness was evaluated with all short-axis
ine images covering the entire ventricle. Volumes were
erived by summation of discs, and the ejection fraction was
alculated accordingly. The LV mass was calculated by
ubtracting endocardial from epicardial volume at end-
iastole and multiplying by 1.05 g/cm3 (11). The extent of
carred myocardium was determined automatically by com-
uter counting of all hyperenhanced pixels in the myocar-
ium on each of the short-axis images. Hyperenhanced
ixels resembling LGE were defined as those with image
ntensities of 2 SDs above the mean of image intensities in
remote myocardial region in the same image, which has
een shown to represent myocardial fibrosis/scarring in
CM by necropsy comparison (12). The scar volume was
hen calculated as a percentage of LV mass (%LV), as the
um of hyperenhanced pixels from each of the short-axis
mages divided by the total number of pixels within the LV
yocardium multiplied by 100%. Also, the surface area was
easured for every patient (Fig. 2).
All CMR analysis was performed with Siemens Argus
oftware (Siemens Healthcare) as well as the National
nstitutes of Health Image Analysis Software Package
National Institutes of Health, Bethesda, Maryland).
linical follow-up. Clinical follow-up was performed by
he Institut für Herzinfarktforschung, Ludwigshafen, Ger-
any, with a standardized telephone questionnaire. In case
f a suspected event, all necessary medical records were
Figure 2 Contrast CMR Analysis
Areas of late gadolinium enhancement (LGE), as defined in the Methods section, w
gap (10 mm). Scar volume was calculated by summation of discs. The scar surfac
the interslice gap (10 mm). The surface area of the entire scar was then also obtabtained and reviewed by the authors acting as an end point
ommittee.
ariables, end points, and definitions. All variables as-
essed were pre-defined and collected directly from patients
nd/or from medical records with a standard questionnaire
nd check list, except CMR parameters, which were evalu-
ted as described in the preceding text. Variables include
eneral characteristics, clinical risk factors for SCD, and
ollow-up results. Most variables are self-explanatory; all
ther variables are defined in the following paragraphs.
Clinical risk factors for SCD: 1) history of cardiac arrest;
) history of spontaneous ventricular tachycardia; 3) extreme
ypertrophy (maximum wall thickness 30 mm); 4) family
istory of SCD (1 first-degree relative, 50 years of
ge); 5) unexplained syncope; and 6) LV outflow tract
radient30 mm Hg measured by continuous-wave Dopp-
er. The LV outflow tract gradient as described in the
receding text was chosen as a surrogate parameter for
bstruction (7), because exercise blood pressure response
as not available in many patients.
There were 2 primary end points: 1) all-cause death; and
) cardiac death. The explicit meaning of these is described
s follows:
All-cause mortality: death from any cause, including
aborted SCD.
Cardiac death: death from all cardiac causes, including
SCD, heart failure, and aborted SCD.
SCD: unexpected arrest of presumed cardiac origin
within 1 h after onset of any symptoms that could be
interpreted as being cardiac in origin (e.g., death after
30 min of angina). If an arrest occurred between 1 and
24 h after onset of symptoms it was classified as
“suspected” sudden death.
Death from congestive heart failure: documented by the
presence of signs of either right ventricular or LV
failure or both on physical exam or radiographic exam.
utlined by computer (red area) in every slice and multiplied with the inter-slice
of each slice was calculated by multiplying the length of the red outline with
y summation of discs.ere o
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Cardiovascular Magnetic Resonance Risk Stratification in HCM September 7, 2010:875–87The diagnosis should be confirmed by noninvasive or
hemodynamic measurements.
Aborted SCD: resuscitation after cardiac arrest defined
as performance of the physical act of cardioversion,
appropriate implantable cardioverter-defibrillator (ICD)
shocks, or cardiopulmonary resuscitation in a patient
who remains alive 28 days later.
Appropriate ICD shocks: defibrillator discharges were
considered appropriate, including automatic defibril-
lation shocks triggered by ventricular tachycardia or
fibrillation and documented by stored intracardiac
electrocardiographic or cycle-length data.
tatistical analysis. Absolute numbers and percentages
ere computed to describe the patient population. Medians
with quartiles) or means (with SD) were computed as
ppropriate. Categorical values were compared by chi-
quare test or Fisher exact test as appropriate. Kaplan Meier
urves were calculated for visualizing the cumulative survival
f patients with and without scar indicated by LGE. A
og-rank test was performed to compare both survival
urves. A multivariable Cox proportional hazard model was
sed for analyzing independent associations with all-cause
nd cardiac mortality. The covariates included in the regres-
ion model as potential confounders were selected with the
resent data and are limited in number due to the number
f observed events. Therefore, the predictive value of LGE
ight be slightly lower than the current estimates from the
ultivariable analysis, due to over-fitting when applying the
ethod to future cases. Values of p  0.05 were considered
ignificant. All p values are results of 2-tailed tests. All
tatistical analyses were performed with the SAS statistical
ackage, version 9.1 (SAS Institute, Cary, North Carolina).
esults
atient characteristics. Two-hundred twenty of all 243
atients were available for clinical follow-up as described in
he preceding text, yielding a follow-up rate of 90.5%. The
emaining 23 patients were lost due to no contact. The
ollowing paragraphs describe the characteristics of the 220
atients who underwent clinical follow-up.
At the time of the CMR study, patients were 58 years of
ge (interquartile range 47 to 68 years). Despite significant
yocardial hypertrophy, most patients were asymptomatic
n  132) or only mildly symptomatic (New York Heart
ssociation functional class I and II, n  46), respectively
Table 1). The remaining baseline characteristics can be
iewed in Table 1.
More than 75% of all patients did not have any recog-
ized clinical risk factors for SCD (n  167). One clinical
isk factor was present in 43 patients (19.5%), and 10
atients had 2 (n  7) or 3 (n  3) clinical risk factors for
CD. Twelve patients were offered prophylactic ICD in-
ertion shortly after the CMR scan, in line with the current
uropean guidelines (7). However, 4 patients initially re- dused ICD placement, mostly due to the lack of clinical
ymptoms.
MR findings. The mean LV ejection fraction was 71%,
anging from 22% to 89%. Most patients had septal hyper-
rophy, followed by apical and concentric patterns defined
ccording to Klues et al. (13) (Table 1). The average
aximum LV wall thickness was 19 mm, and the average
V mass was 156 g (Table 1).
Wall motion abnormalities were present in 17 of our 220
atients. In all 17 patients the wall motion abnormality was
ithin the area of hypertrophy and scarring except in 3
atients, in whom the wall motion abnormality was con-
ned to the thinned apical segments in the setting of
assive mid-ventricular septal hypertrophy.
LGE was present in 148 (67.2%) of our 220 mostly
ildly or asymptomatic patients. In those patients scar
urden ranged from 0.9% to 39.9% of LV mass. The
aseline Patient CharacteristicsTable 1 Baseline Patient Characteristics
n or IQR
All patients with follow-up (%) 100 220
Time to follow-up (days, median) 1,090 466–1,869
Height (cm) 174 168–182
Weight (kg) 80 70–91
Female (%) 38.6 85/220
Symptoms (%)
Chest pain 11.3 25/220
NYHA functional class I 1.4 3/220
NYHA functional class II 19.5 43/220
NYHA functional class III 7.72 17/220
Pattern (%)
Septal 84.1 185/220
Apical 8.2 18/220
Concentric 7.7 17/220
CMR parameters
LVEF (%) 71 65–77
Maximal wall thickness (mm) 19 16–23
LV mass (g) 156 127–196
LV mass index (g/m2) 84 68–97
LVOT obstruction (%) 31.4 69/220
LGE mass (g) 2.2 0.0–8.5
LGE (% of LVM) 1.3 0.0–5.5
Surface area/LV mass (mm2/g) 0.6 0.0–1.9
Surface area LGE (mm2) 100.0 0.0–333.4
SCD risk factors (%)
Maximal wall thickness 30 mm 3.6 8/220
History of sustained VT 5.5 12/220
Family history of SCD 4.5 10/220
Unexplained syncope 5.5 12/220
LVOT obstruction 30 mm Hg 10.9 24/220
Events (%)
All-cause mortality 10.0 22/220
Cardiac mortality 7.2 16/220
ll patients with follow-up.
CMR  cardiovascular magnetic resonance; EF  ejection fraction; IQR  interquartile range;
GE  late gadolinium enhancement; LV  left ventricle; LVOT  left ventricular outflow tract;
YHA  New York Heart Association functional class; SCD  sudden cardiac death; VT 
entricular tachycardia.istribution of scar burden throughout the patient cohort
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. Table 2 compares the characteristics of patients with
GE (n  148) with those without LGE (n  72). In
Figure 3 Bar Graph Visualizing the Distribution of Scar Burden
Median scar percentage of left ventricular mass (%LV). It is important to note that
or asymptomatic hypertrophic cardiomyopathy population, scarring was present as
atients Without LGE Compared With Patients With LGETable 2 Patients Without LGE Compared With Patients With LG
No LGE
LGE (n) 72
Age (yrs) 55.0
Pattern
Septal 88.9 (64/72)
Apical 5.6 (4/72)
Concentric 5.6 (4/72)
CMR
LVEF (%) 70.5
Maximal wall thickness (mm) 18.0
LV mass (g) 147.0
LV mass index (g/m2) 76.0
LVOT obstruction (%) 34.7
LGE (g) 0
LGE (% of LVM) (%) 0
Surface area LGE (mm2) 0
Surface area/LV mass (mm2/g) 0
SCD risk factors
Maximal wall thickness 30 mm 0 (0/72)
History of spontaneous VT 0 (0/72)
Family history of SCD 2.8 (2/72)
Unexplained syncope 4.2 (3/72)
LVOT obstruction 30 mm Hg 14.3 (9/63)
Number of SCD risk factors
0 83.3 (60/72)
1 13.9 (10/72)
2 2.8 (2/72)
3 0.0 (0/72)alues are % (n/N) unless otherwise indicated.
CI  confidence interval; OR  odds ratio; other abbreviations as in Table 1.eneral there were no differences between groups, except
hat patients with scar had a higher burden of hypertro-
hy as well as a history of arrhythmias more frequently.
r Patient Cohort
g most individuals in our largely low
ted by late gadolinium enhancement.
LGE p Value OR (95% CI)
148 — —
59.5 0.50 1.01 (0.99–1.03)
81.8 (121/148) 0.17 0.56 (0.24–1.30)
8.8 (13/148) 0.40 1.64 (0.51–5.21)
9.5 (14/148) 0.32 1.78 (0.56–5.60)
71.0 0.95 0.99 (0.97–1.02)
20.0 0.01 1.13 (1.05–1.21)
162.0 0.05 1.01 (1.00–1.01)
85.0 0.001 1.01 (1.00–1.02)
29.7 0.45 0.80 (0.44–1.45)
5.7 — —
3.2 — —
211.6 — —
1.4 — —
5.4 (8/148) 0.05 N/A
8.1 (12/148) 0.05 N/A
5.4 (8/148) 0.38 2.00 (0.41–9.67)
6.1 (9/148) 0.56 1.49 (0.39–5.68)
11.4 (15/132) 0.56 0.77 (0.32–1.87)
73.8 (107/148) 0.07 0.52 (0.25–1.07)
21.3 (33/148) 0.14 1.78 (0.82–3.85)
9.1 (5/148) 0.81 1.22 (0.23–6.47)
2.0 (3/148) 0.22 N/Ain Ou
, amon
indicaE
Characteristics of All Patients With EventsTable 3 Characteristics of All Patients With Events
Case # Event Type Age, yrs NYHA CCS
MWT
>30 mm
Spontaneous
VT
History
of SCD
Unexplained
Syncope
LVOT
>30 LVEF MWT
LV
Mass LGE
LGE
(g)
LGE
(% LV)
Surface
Area
Surface
Area/
LV Mass
3 Cancer 71 — — — — — — — 80 15 82 X 0.9 1.2 51.4 0.6
5 SCD 60 — — — — — — — 72 18 132 X 19.5 14.8 374.2 2.8
7 Suspected SCD 60 — — — — — — X 85 23 214 X 14.1 6.6 483.2 2.3
11 Heart failure 83 — — — — — — — 65 15 123 X 8.1 6.6 190.6 1.6
28 Cancer 78 2 — — — — — — 59 15 162 X 1.5 0.9 112.6 0.7
42 Cancer 74 — — — — — — — 78 23 264 X 44.0 16.6 878.9 3.3
70 SCD 62 — — — — — — — 30 21 210 X 83.6 39.9 2,347.7 11.2
74 Suspected SCD 64 — — — — — — — 53 18 117 X 27.0 23.1 1,034.8 8.9
80 Heart failure 79 — — — — — — X 89 26 177 X 8.0 4.5 284.9 1.6
107 Aborted SCD 48 — — X X — X — 67 32 265 X 92.9 35.1 1,924.5 7.3
112 Suspected SCD 51 — — — — — — — 22 13 454 X 3.9 0.9 172.7 0.4
113 Cancer 66 — — — — — — X 58 25 282 X 2.9 1.0 174.9 10.6
119 Heart failure 76 — — — — — — — 68 20 158 X 3.6 2.3 169.3 11.1
124 SCD 61 — — — — — — — 58 18 216 X 18.9 8.7 664.9 3.1
136 SCD 53 — — — — — — — 79 26 196 — 0.0 0.0 0.0 0.0
139 Suspected SCD 61 — — — — — — — 78 20 173 X 9.7 5.6 249.2 1.4
154 Accident 60 — — — — — — — 72 18 190 X 14.5 7.6 681.3 3.6
161 Suspected SCD 67 — — — — — — — 68 23 154 X 17.2 11.2 508.4 3.3
163 Aborted SCD 54 — — — X — — — 69 29 259 X 51.3 19.8 1,655.0 18.0
169 Heart failure 76 3 1 — — X X — 49 17 243 X 19.8 8.2 412.0 1.7
201 Heart failure 70 — — — — — — — 46 16 147 X 2.4 1.6 180.7 1.2
236 Cancer 86 — — — — — X X 70 18 168 — 0.0 0.0 0.0 0.0
CCS  Canadian Cardiovascular Society Angina Score; MWT  maximum wall thickness; NYHA  New York Heart Association functional class; SCD  sudden cardiac death; other abbreviations as in Table 1.
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September 7, 2010:875–87 Cardiovascular Magnetic Resonance Risk Stratification in HCMScarring was always located in the area of hypertrophy,
ither patchy with multiple foci (62.8%) or in a more diffuse
istribution (37.2%). In contrast to subendocardial scarring
n ischemic or subepicardial scarring in inflammatory heart
isease, scars were predominantly located within the mid-
yocardium in the HCM patient group.
ollow-up results. During the follow-up time (mean
,090 days) (Table 1) 20 (9%) of the 220 patients died, and
patients survived SCD due to adequate ICD discharge.
hose 2 patients were also counted as events as described in
he Methods section. Most events (n  16) occurred for
ardiac reasons, the remaining 6 events were related to
ancer and accidents. The clinical and imaging characteris-
ics of all patients with events are displayed in Table 3. Note
hat 20 of the 22 (91%) patients who died during follow-up
ad no previous clinical symptoms. In addition, 8 of the 11
atients (73%) suffering from SCD during follow-up had no
ecognized clinical risk factors for SCD.
redictors of events. For evaluation of predictors for
vents we looked at: 1) all patients who suffered any type of
eath during follow-up (all-cause mortality); 2) the sub-
roup of patients who suffered cardiac death (cardiac mor-
ality); and 3) the subgroup of patients suffering SCD. The
nivariate analysis comparing different general, clinical, and
maging characteristics between groups with and without an
nivariate Analysis: All-Cause MortalityTable 4 Univariate Analysis: All-Cause Mortality
No Event (n  198)
Age, yrs 56.5 (46.0–68.0)
Pattern
Septal 84.3 (167)
Apical 7.1 (14)
Concentric 8.6 (17)
CMR parameter
LVEF, % 71.0 (64.9–76.7)
Maximal wall thickness, mm 19.0 (16.0–22.0)
LV mass, g 154.0 (126.8–190.3)
LV mass index, g/m2
LVOT obstruction, % 36.4 (61)
LGE 64.6 (128)
LGE, g 1.8 (0.0–7.4)
LGE, % LV 1.2 (0.0–4.6)
Surface area LGE, mm2 74.1 (0.0–263.6)
Surface area/LV mass, mm2/g 0.5 (0.0–1.7)
SCD risk factors
Maximal wall thickness 30 mm 3.5 (7)
History of spontaneous VT 5.0 (10)
Family history of SCD 2.0 (9)
Unexplained syncope 2.0 (9)
LVOT obstruction 30 mm Hg 10.0 (20)
Number of SCD risk factors
0 76.7 (152)
1 19.6 (39)
2 2.5 (5)alues are median (interquartile range) or % (n).
Abbreviations as in Tables 1 and 2.vent during follow-up is displayed in Table 4 (all-cause
ortality), Table 5 (cardiac mortality), and Table 6 (SCD
nly). There was no significant correlation among the
ypertrophy pattern (septal, apical, or concentric), LV
unction, and the presence of wall motion abnormalities. In
act, none of the 17 patients with wall motion abnormalities
uffered an event. Furthermore, we found no significant
orrelation between the occurrence of an adverse event and
he presence of any single clinical risk factor. Also the
resence of any 2 (n  6) clinical risk factors was not
ignificant for prediction of events (Tables 4, 5, and 6).
owever, besides the LV mass and patient age, only the
resence of LGE as well as all LGE-related parameters
eached statistical significance. In fact, the presence of any
GE yielded an odds ratio for death of 5.47 in the all-cause
ortality and 8.01 in the cardiac mortality group. When
ocusing on the subgroup of patients suffering SCD only,
he presence of LGE almost reached statistical significance,
ielding an odds ratio for SCD of 5.14 (Table 6).
Figure 4 displays the relationship of scar burden assessed as
LV and the number of clinical risk factors as well as adverse
vents (right 2 columns). In general, patients with clinical risk
actors for SCD had a larger amount of scar by CMR than
atients without risk factors. However, even patients with 2
linical risk factors had significantly less scarring than patients
Cause Mortality (n  22) p Value OR (95% CI)
65.0 (60.0–76.0) 0.01 1.06 (1.02–1.02)
81.8 (18) 0.76 0.84 (0.26–2.64)
13.6 (3) 0.39 2.08 (0.55–7.87)
4.5 (1) 1.00 0.51 (0.06–4.01)
68.0 (58.0–78.0) 0.17 0.96 (0.93–1.00)
19.0 (17.0–23.0) 0.57 1.03 (0.94–1.13)
183.0 (153.5–243.2) 0.05 1.01 (1.00–1.01)
30.8 (8) 0.59 1.28 (0.51–3.22)
90.1 (20) 0.01 5.47 (1.24–24.08)
11.9 (2.9–19.8) 0.001 1.02 (1.00–1.03)
6.6 (1.2–14.8) 0.01 1.04 (1.00–1.07)
329.6 (172.7–681.3) 0.001 1.00 (1.00–1.00)
1.7 (0.7–3.3) 0.001 1.16 (1.02–1.32)
4.5 (1) 0.58 1.30 (0.15–11.08)
9.1 (2) 0.34 1.88 (0.38–9.19)
4.5 (1) 1.00 1.00 (0.12–8.29)
13.6 (3) 0.11 3.32 (0.83–13.30)
19.0 (4) 0.30 1.81 (0.55–5.92)
68.2 (15) 0.37 0.65 (0.25–1.69)
18.2 (4) 1.00 0.91 (0.29–2.83)
9.1 (2) 0.15 3.86 (0.7–21.2)All-
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Cardiovascular Magnetic Resonance Risk Stratification in HCM September 7, 2010:875–87ith an event. So the mean scar burden of patients with 2 risk
actors was 3.8%, whereas the mean scar burden was 11.8% in
he group of individuals who suffered from cardiac death and
.8% when all-cause mortality was considered.
Kaplan-Meier survival curves—for all-cause mortality,
ardiac mortality, and SCD comparing patients with scar
ith patients without scar—can be viewed in Figures 5A to
C. Note that during the first 1,825 days of follow-up not
single patient without scar suffered from any cardiac death,
ncluding SCD (Figs. 5B and 5C).
Multivariable Cox regression analysis, including the pres-
nce of LGE, LV ejection fraction, and LV myocardial
ass, also revealed LGE as a good independent predictor of
ardiac death (p  0.035; hazard ratio [HR]: 4.81). In this
odel ejection fraction (p  0.067; HR: 0.96), and LV
ass (p  0.40; HR: 1.00) did not reach statistical signif-
cance. When the presence of 1 and 2 clinical risk factors for
CD as well as the presence of LGE was included in the
ultivariable regression analysis, the presence of LGE was
good independent predictor of cardiac death (p  0.038,
R: 8.6), whereas the presence of 1 (p  0.63, HR: 0.73)
r 2 clinical risk factors (p  0.68, HR: 1.37) did not reach
tatistical significance in our cohort. We did not perform
ultivariable analysis in the subgroup of patients suffering
nivariate Analysis: Cardiac MortalityTable 5 Univariate Analysis: Cardiac Mortality
No Cardiac Mortality (n  204)
Age, yrs 57.0 (46.0–68.0)
Pattern
Septal 84.3 (172)
Apical 7.4 (15)
Concentric 8.3 (17)
CMR parameter
LVEF, % 71.0 (64.8–76.9)
Maximal wall thickness, mm 19.0 (16.0–22.5)
LV mass, g 154.8 (126.8–190.9)
LV mass index, g/m2 81.4 (66.2–95.3)
LVOT obstruction, % 30.9 (63.0)
LGE 65.2 (133.0)
LGE, g 1.8 (0.0–7.4)
LGE, % LV 1.1 (0.0–4.6)
Surface area LGE, mm2 75.6 (0.0–272.3)
Surface area/LV mass, mm2/g 0.5 (0.0–1.7)
SCD risk factors
Maximal wall thickness 30 mm 3.4 (7.0)
History of spontaneous VT 4.9 (10.0)
Family history of SCD 4.4 (9.0)
Unexplained syncope 4.9 (10.0)
LVOT obstruction 30 mm Hg 12.2 (22.0)
Number of SCD risk factors
0 76.5 (156.0)
1 19.6 (40.0)
2 2.9 (6.0)
alues are median (interquartile range) or % (n).
Abbreviations as in Tables 1 and 2.CD (n  11), due to the limited number of events. niscussion
his study was unique in that we could demonstrate that the
resence of scar visualized by LGE CMR is a predictor for
eath in HCM patients. In comparison with those of
revious studies, our primary end points were not arrhyth-
ias (6,14) or ventricular remodeling (15) but all-cause and
ardiac mortality only. Our data indicate that the presence
f LGE might be useful for noninvasive risk stratification in
symptomatic and mildly symptomatic HCM patients,
ielding an odds ratio of 5.47 for all-cause and 8.01 for
ardiac mortality. This might be superior to classic clinical
isk factors, because in our dataset the presence of 2 risk
actors yields an odds ratio of 3.86 for all-cause and 2.20 for
ardiac mortality, respectively (Tables 4 and 5). Further-
ore, multivariable analysis revealed the presence of LGE
s a good independent predictor of death in HCM patients.
atient characteristics. Most patients were only mildly or
ompletely asymptomatic (81%), which is similar to our
revious results (95%) (11) as well as to patient cohorts of
oon et al. (15) (97%) and Adabag et al. (6) (95%). The
nding that most HCM patients are low or asymptomatic
nderscores the importance of new risk stratification strat-
gies, because SCD might be the first clinical symptom,
ccurring without any warning years after the initial diag-
Cardiac Mortality (n  16) p Value OR (95% CI)
61.5 (57.0–73.0) 0.05 1.04 (1.00–1.08)
81.2 (13) 0.72 0.81 (0.22–2.99)
12.5 (2) 0.36 1.80 (0.37–8.67)
6.2 (1) 1.00 0.73 (0.09–5.90)
68.0 (51.2–75.2) 0.05 0.95 (0.92–0.99)
20.0 (17.5–24.5) 0.35 1.05 (0.95–1.16)
186.0 (150.3–229.7) 0.05 1.01 (1.00–1.01)
97.1 (82.0–126.0) 0.01 1.02 (1.00–1.03)
37.5 (6.0) 0.58 1.34 (0.47–3.86)
93.8 (15.0) 0.05 8.01 (1.04–61.9)
15.6 (5.9–23.4) 0.001 1.02 (1.00–1.04)
7.4 (3.4–17.3) 0.001 1.05 (1.01–1.09)
393.1 (185.7–849.9) 0.001 1.00 (1.00–1.00)
2.0 (1.3–4.8) 0.001 1.20 (1.05–1.38)
6.3 (1.0) 0.46 1.88 (0.22–16.27)
12.5 (2.0) 0.21 2.77 (0.55–13.90)
6.3 (1.0) 0.54 1.44 (0.17–12.18)
12.5 (2.0) 0.21 2.77 (0.55–13.90)
13.3 (2.0) 1.00 1.10 (0.23–5.23)
68.8 (11.0) 0.54 0.68 (0.22–2.04)
18.8 (3.0) 1.00 0.95 (0.26–3.48)
6.3 (1.0) 0.38 2.20 (0.25–19.48)osis of HCM has been made (2,3).
I
(
t
c
C
t
t
T
d
U
V
883JACC Vol. 56, No. 11, 2010 Bruder et al.
September 7, 2010:875–87 Cardiovascular Magnetic Resonance Risk Stratification in HCMOnly 12 of our 220 patients were eligible for prophylactic
CD insertion according to the current European guidelines
7). However, 4 patients initially refused ICD placement due
o the lack of clinical symptoms, reflecting the current diffi-
ulties in real-world clinical HCM patient management.
nivariate Analysis: SCDTable 6 Univariate Analysis: SCD
No SCD (n  209)
Age, yrs (IQR) 57.0 (46.0–68.0)
Pattern
Septal 84.2 (176.0)
Apical 7.7 (16.0)
Concentric 8.1 (17.0)
CMR parameter
LVEF, % (IQR) 71.0 (64.7–76.7)
Maximal wall thickness, mm (IQR) 19.0 (16.0–22.0)
LV mass, g (IQR) 155.2 (126.8–190.3)
LV mass index, g/m2 81.5 (66.9–95.5)
LVOT obstruction, % (IQR) 30.6 (64.0)
LGE 66.0 (138.0)
LGE, g (IQR) 1.9 (0.0–7.6)
LGE, % LV (IQR) 1.3 (0.0–4.7)
Surface area LGE, mm2 (IQR) 79.9 (0.0–280.9)
Surface area/LV mass, mm2/g (IQR) 0.6 (0.0–1.7)
SCD risk factors
Maximal wall thickness 30 mm 3.3 (7.0)
History of spontaneous VT 4.8 (10.0)
Family history of SCD 2.0 (9.0)
Unexplained syncope 2.0 (9.0)
LVOT obstruction 30 mm Hg 12.4 (23.0)
Number of SCD risk factors
0 76.1 (159.0)
1 19.6 (39.0)
2 3.3 (7.0)
alues are median (interquartile range) or % (n).
Abbreviations as in Tables 1 and 2.
Figure 4 Bar Graph Plotting the Number of Sudden Cardiac Dea
and All-Cause and Cardiac Mortality Versus the Amou
Percentage of left ventricular mass (%LV). Note that patients who suffered an even
follow-up had the highest scar burden. Interestingly, patients without clinical risk fMR findings. As expected, septal hypertrophy was de-
ected most frequently, whereas apical and concentric pat-
erns were present in approximately 8% of patients each.
he average maximum wall thickness of 19 mm nicely
emonstrates that significant hypertrophy can be present in
SCD (n  11) p Value OR (95% CI)
60.0 (53.0–62.0) 0.77 1.07 (0.97–1.05)
81.8 (9.0) 0.69 0.84 (0.17–4.08)
9.1 (1.0) 0.60 1.21 (0.15–10.03)
9.1 (1.0) 1.00 1.13 (0.14–9.36)
68.2 (53.2–78.0) 0.05 0.95 (0.92–0.99)
21.0 (18.0–26.0) 0.13 1.09 (0.98–1.21)
210.0 (153.5–259.2) 0.05 1.01 (1.00–1.02)
97.0 (83.9–135.8) 0.05 1.02 (1.01–1.04)
45.5 (5.0) 0.33 1.89 (0.55–6.41)
90.9 (10.0) 0.10 5.14 (0.65–41.0)
18.9 (9.7–51.3) 0.001 1.02 (1.01–1.04)
11.2 (5.6–23.1) 0.01 1.06 (1.02–1.11)
508.4 (249.2–1,655.0) 0.001 1.00 (1.00–1.00)
3.1 (1.4–7.3) 0.01 1.26 (1.08–1.47)
9.1 (1.0) 0.34 2.89 (0.32–25.77)
18.2 (2.0) 0.11 4.42 (0.84–23.23)
0 (0.0) 1.00 N/A
9.1 (1.0) 0.47 1.80 (0.21–15.35)
10.0 (1.0) 1.00 0.78 (0.09–6.47)
72.7 (8.0) 0.73 0.84 (0.21–3.28)
18.2 (2.0) 1.00 0.91 (0.19–4.38)
0.0 (0) 1.00 N/A
isk Factors
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Cardiovascular Magnetic Resonance Risk Stratification in HCM September 7, 2010:875–87argely low or asymptomatic patients, confirming data from
ther groups (6,15).
LGE was present in almost 70% of patients, mostly
onfined to the area of hypertrophy, either in focal or
iffuse patchy distribution, confirming previous findings
11). Figure 3 displays the distribution of scar burden
hroughout the patient cohort, demonstrating that most
Figure 5 Kaplan-Meier Survival Curves With Regard to All-Caus
All-cause mortality (A), cardiac mortality (B), and SCD (C). The number of patients
the group without any scar not a single patient suffered cardiac death (B, C) durinatients had a scar volume between 1% and 9% of sheir LV mass. Only 36 patients had more than 10% of
car.
ollow-up results and predictors of events. In the group
f 22 patients suffering death during follow-up, most
ndividuals died from cardiac events (n  16), emphasizing
hat cardiac events are the main cause of mortality among
argely low or asymptomatic HCM patients. In this clinical
rtality, Cardiac Mortality, and SCD
k is shown at the bottom of the figure. Note that in
first 5 years of follow-up. Abbreviations as in Figure 1.e Mo
at ris
g thecenario, however, risk stratification based on conventional
c
2
s
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September 7, 2010:875–87 Cardiovascular Magnetic Resonance Risk Stratification in HCMlinical risk factors (4,5) remains difficult, because 20 of the
2 patients (91%) who died during follow-up had no clinical
ymptoms, and only 3 of the 11 patients (27%) suffering
Figure 6 CMR Images
(A) CMR images of a 39-year-old white man without recognized risk factors for SCD. C
presence of severe septal hypertrophy. However, no scarring could be detected by con
follow-up. (B) CMR images of a 64-year-old white man (case #74, Table 3), also witho
function compared with the patient in A (upper 2 rows), LGE revealed significant myoc
of any recognized risk factor, underscoring that myocardial scarring might be a betterCD had any recognized risk factors for SCD (Table 3). sThus, CMR might hold promise to improve clinical
atient management and ultimately save lives. We found
hat the presence of scar as demonstrated by LGE is the
ages (top and middle rows) reveal normal left ventricular ejection fraction in the
MR (bottom rows). As expected, this patient did not suffer any event during
recognized risk factors. However, despite similar morphology and left ventricular
scarring (white arrows). This patient suffered SCD during follow-up in the absence
or of major adverse cardiac events. Abbreviations as in Figure 1.ine im
trast C
ut any
ardial
predicttrongest predictor for death in HCM patients with an odds
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Cardiovascular Magnetic Resonance Risk Stratification in HCM September 7, 2010:875–87atio of 5.47 for all-cause and 8.01 for cardiac mortality,
espectively. Albeit limited by the relatively low number of
ases and events, multivariable Cox regression analysis
onfirmed the presence of LGE as a good independent
redictor of cardiac death when compared with LV function
nd LV mass (p  0.035; HR: 4.81) as well as when
ompared with the presence of 1 or 2 clinical risk factors
p  0.038, HR: 8.6), respectively.
This finding nicely fits with the fact that ventricular
rrhythmias are the pathophysiological substrate of SCD in
CM patients (16) and that the presence of LGE was
ssociated with a 7-fold increase in the risk of nonsustained
entricular tachycardia at follow-up in the cohort of Adabag
t al. (6). In addition, as shown by Moon et al. (15), LGE
s related not only to arrhythmias but also to ventricular
emodeling and heart failure in HCM patients. All these
revious results might explain why in the present study not
single patient without myocardial scarring suffered cardiac
eath (including SCD) during the first 1,825 days of
ollow-up (Figs. 5B and 5C).
This concept is also highlighted by Figure 6, displaying 2
ypical examples of patients without any traditional risk
actors but remarkable differences in scar size and outcome.
atient A with no presence of scar by LGE had no event
uring the follow-up period. However, Patient B, with a
rominent scar, died from SCD. In fact, 8 of the 11 patients
uffering from SCD during follow-up had no recognized
linical risk factors, but all had scars except 1. This patient,
ho suffered SCD without any recognized clinical risk
actors and without any LGE (Table 3, Case #136),
nderscores that additional parameters such as genotype
17) or undetected coronary artery disease might also play a
ole in the clinical course of HCM.
Despite our encouraging data, however, it is important to
eep in mind that there is not a 1:1 relationship between the
resence of LGE and cardiac death. Thus, to further
mprove possible CMR risk stratification, we looked at the
ncremental value of several additional CMR-related pa-
ameters, such as the scar surface area (Fig. 2), which is
hought to cause electrical instability (18). Interestingly, all
hese parameters reached statistical significance in the uni-
ariate analysis (Tables 4 to 6). However, we were not able
o discriminate their individual predictive potential, due to
he limited number of cases and events available in the
resent study. This topic as well as the question of whether
he location of scarring within the ventricle might also help
redict events (19) will be revisited as soon as the HCM
ata of the EuroCMR Registry (20,21) will be available.
linical implications. Although our data demonstrate
n association between LGE and death in HCM pa-
ients, prospectively designed studies in large patient
opulations—such as the EuroCMR Registry (20,21)—are
till required to definitively establish LGE as causally related
o the death risk. However, with regard to our data and the
esults from other groups demonstrating that LGE is the
ubstrate for ventricular arrhythmias in HCM (6,14) as wells associated to ventricular remodeling and heart failure
15), it might be time to start regarding LGE as a primary
isk factor for HCM patients.
Consequently, we believe that some weight can already be
iven to the presence of LGE as an arbitrator in reaching
ecommendations for prophylactic ICDs, when ambiguity
emains concerning individual patient risk of cardiac death
fter assessing the conventional risk factors (22). Neverthe-
ess, large longitudinal follow-up studies are needed to
efinitely establish LGE as an independent predictor of
ardiac death in HCM.
onclusions
mong our population of largely low or asymptomatic HCM
atients, the presence of scar indicated by LGE is a good
ndependent predictor of all-cause mortality as well as of
ardiac mortality. These data support the necessity for future
arge longitudinal follow-up studies to definitely establish
GE as an independent predictor of cardiac death in HCM as
ell as to evaluate the incremental prognostic value of addi-
ional CMR parameters, such as scar surface area.
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